$PFSA

Profusa Announces 1-for-25 Reverse Stock Split; Stock Down

Profusa, Inc. (PFSA) will conduct a 1-for-25 reverse stock split effective July 7, 2026, keeping the PFSA ticker. The company says shares outstanding will fall from about 13.2M to ~530,000; par value and shareholder rights are unchanged aside from share count. Fractional shares won’t be issued; cash will be paid in lieu. PFSA closed at $0.09 (-28.08%).

Original reporting
Published Jul 3, 2026, 9:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 3, 2026, 9:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Profusa Announces 1-for-25 Reverse Stock Split; Stock Down — source image
Decision brief

The 30-second read

$PFSABearishMed
01

Why it matters

The corporate action reduces share count materially (about 13.2M to ~530k) while keeping par value unchanged; fractional handling is via cash-in-lieu, which can create short-term trading/settlement effects.

02

Market read

Traders need to adjust for the effective-date corporate action and anticipate volatility given the stock’s steep recent decline and repeated reverse-split history.

03

What to watch

The article doesn’t state the reason for the split, any concurrent financing, or compliance status—those missing details could dominate the stock’s next move more than the split mechanics.

Relevance 5/10Novelty 6/10Timing: Effective July 7, 2026 (corporate action) with trading under PFSA in the interim.

Background

Profusa previously executed a 1-for-75 reverse split on Feb. 9, 2026; this new action is another consolidation (1-for-25) effective July 7, 2026.

Company-level read

Ticker impact

$PFSABearishMedium confidence
Context

Profusa announces a 1-for-25 reverse split effective July 7, 2026, with shares reduced to ~530,000 and no change to par value.

Expected impact

Likely continued volatility and downside pressure around the effective date, with potential short-term technical selling/positioning ahead of July 7.

Evidence & confidence

The article provides a concrete, time-bound corporate action (effective July 7) plus a sharp recent close down 28.08%, which together typically drive risk-off trading in microcaps.

Market effects

Limited read-across; this is company-specific microcap financing optics rather than a sector catalyst.

Minimal; Berkeley-based issuer with no broader regional macro linkage in the text.

Low; no international deal/regulatory/financing terms disclosed beyond the split mechanics.

Counterpoint

The reverse split itself doesn’t change fundamentals; it may improve listing/price optics and reduce dilution pressure if the company is managing compliance or capital structure.

Key entities

  • Profusa, Inc.

    Announces 1-for-25 reverse stock split effective July 7, 2026; shares reduced to ~530,000; ticker remains PFSA.

Related articles

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).